Does Rallies show 13F holders for RVMD?

Yes. Rallies tracks hedge fund and 13F ownership data for RVMD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RVMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RVMD. It does not provide personalized investment advice.

RVMD (Revolution Medicines, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Revolution Medicines, Inc. Common Stock (RVMD) is a publicly traded Healthcare sector company. As of May 20, 2026, RVMD trades at $150.91 with a market cap of $30.69B and a P/E ratio of -24.94. RVMD moved +1.94% today. Year to date, RVMD is +91.92%; over the trailing twelve months it is +271.46%. Its 52-week range spans $29.17 to $155.70. Analyst consensus is strong buy with an average price target of $176.95. Rallies surfaces RVMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RVMD stock?

Hedge funds tracked by Rallies that own RVMD include Farallon Capital, Duquesne Family, A16Z Perennial, Orbimed Advisors, and Davidson Kempner. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Revolution Medicines, Inc. Common Stock.

RVMD Key Metrics

Key financial metrics for RVMD
Metric	Value
Price	$150.91
Market Cap	$30.69B
P/E Ratio	-24.94
EPS	$-5.95
Dividend Yield	0.00%
52-Week High	$155.70
52-Week Low	$29.17
Volume	2.04M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-1.13B
Gross Margin	0.00%

Top Hedge Funds Holding RVMD

Farallon Capital holds 13.60M shares of RVMD, changed -6.71% as of Mar 31, 2026.
Duquesne Family holds 315.86K shares of RVMD, changed +0.00% as of Mar 31, 2026.
A16Z Perennial holds 104.21K shares of RVMD, changed -43.03% as of Mar 31, 2026.
Orbimed Advisors holds 52.00K shares of RVMD, changed +100.77% as of Mar 31, 2026.
Davidson Kempner holds 27.07K shares of RVMD, changed +0.00% as of Mar 31, 2026.

Latest RVMD News

RVMD slides after Needham target cut tied to raised 2026 cost guidance — May 7, 2026
Revolution Medicines’ Daraxonrasib Phase 1/2 Data Show Durable Responses, OS Benefit — May 6, 2026
RVMD climbs as FDA clears expanded-access path for pancreatic cancer drug daraxonrasib — May 4, 2026
RVMD slips as investors price in $2.2B equity-and-convert financing overhang — May 1, 2026
Revolution Medicines slides as April $2.2B financing overhang persists — Apr 29, 2026

Recent RVMD Insider Trades

Mancini Anthony sold 1.67K (~$220.01K) on Apr 27, 2026.
Mancini Anthony sold 1.05K (~$139.39K) on Apr 27, 2026.
Mancini Anthony sold 400 (~$53.73K) on Apr 27, 2026.

RVMD Analyst Consensus

20 analysts cover RVMD: 0 strong buy, 20 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $176.95.

Common questions about RVMD

Who owns RVMD stock?: Hedge funds tracked by Rallies that own RVMD include Farallon Capital, Duquesne Family, A16Z Perennial, Orbimed Advisors, and Davidson Kempner. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Revolution Medicines, Inc. Common Stock.
Does Rallies show 13F holders for RVMD?: Yes. Rallies tracks hedge fund and 13F ownership data for RVMD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RVMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RVMD. It does not provide personalized investment advice.